Vanda Pharmaceuticals, Inc. (VNDA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162364,
    "name": "Vanda Pharmaceuticals, Inc.",
    "stock_name": "Vanda Pharmaceuticals, Inc.",
    "full_name": "Vanda Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/vanda-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.20",
    "chg": 0.28,
    "chgp": "5.69%",
    "dir": 1,
    "prev_price": "4.92",
    "mcapval": "268.86",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US9216591084",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.92 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vanda-pharmaceuticals-inc-1162364-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vanda Pharmaceuticals Hits New 52-Week High at $5.62",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vanda-pharmaceuticals-hits-new-52-week-high-at-562-3649242",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VandaPharmaceut_priceRelatedfactors_3649242.png",
        "date": "2025-10-27 16:50:44",
        "description": "Vanda Pharmaceuticals, Inc. achieved a new 52-week high of USD 5.62 on October 24, 2025, despite a 1-year performance decline of 8.03%. The company, with a market capitalization of USD 269 million, is currently loss-making and does not offer dividends, reflecting its challenges in the pharmaceutical sector."
      },
      {
        "title": "Vanda Pharmaceuticals Hits New 52-Week High of $5.59",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vanda-pharmaceuticals-hits-new-52-week-high-of-559-3608004",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VandaPharmaceut_priceRelatedfactors_3608004.png",
        "date": "2025-10-09 20:08:43",
        "description": "Vanda Pharmaceuticals, Inc. achieved a new 52-week high of USD 5.59 on October 8, 2025, despite a 1-year performance decline of 8.7%. The company, with a market capitalization of USD 269 million, remains loss-making and does not offer a dividend yield, reflecting its growth stage in the pharmaceuticals industry."
      },
      {
        "title": "Vanda Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vanda-pharmaceuticals-forms-golden-cross-signaling-potential-bullish-breakout-3595284",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VandaPharmaceut_goldencross_3595284.png",
        "date": "2025-10-06 15:28:41",
        "description": "Vanda Pharmaceuticals, Inc. has recently achieved a Golden Cross, indicating a potential shift in market sentiment. The stock has shown strong daily and weekly performance, outperforming the S&P 500. Despite past declines over three and five years, recent bullish indicators suggest renewed investor interest in the company."
      },
      {
        "title": "Vanda Pharmaceuticals Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vanda-pharmaceuticals-forms-death-cross-signaling-potential-bearish-trend-ahead-3565416",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/VandaPharmaceut_dealthcross_3565416.png",
        "date": "2025-09-24 14:19:54",
        "description": "Vanda Pharmaceuticals has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators present a mixed outlook, with some showing bullish momentum while others suggest short-term challenges. Over the long term, the company has underperformed significantly compared to the S&P 500, raising investor concerns."
      },
      {
        "title": "Is Vanda Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vanda-pharmaceuticals-inc-technically-bullish-or-bearish-3547153",
        "imagepath": "",
        "date": "2025-09-20 19:48:20",
        "description": "As of 11 September 2025, the technical trend for Vanda Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing both bullish and bearish signals. The MACD is mildly bullish on both weekly and monthly time frames, while the daily moving averages also indicate a mildly bullish trend. However, the KST, Dow Theory, and OBV are all mildly bearish on the weekly and monthly time frames, suggesting underlying weakness. The Bollinger Bands show a sideways trend weekly but bearish monthly. \n\nIn terms of performance, Vanda Pharmaceuticals has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.64% versus the S&P 500's 12.22%, and a one-year return of -8.69% compared to 17.14% for the index...."
      },
      {
        "title": "Is Vanda Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vanda-pharmaceuticals-inc-overvalued-or-undervalued-3543583",
        "imagepath": "",
        "date": "2025-09-20 18:23:19",
        "description": "As of 8 May 2024, the valuation grade for Vanda Pharmaceuticals, Inc. has moved from expensive to risky, indicating a significant downgrade in its perceived value. The company is currently considered overvalued based on its financial metrics, particularly with a Price to Book Value of 0.53, an EV to EBIT of 0.89, and an EV to EBITDA of 1.00. Compared to peers, Vanda's valuation ratios are less favorable, with Lexicon Pharmaceuticals, Inc. showing a P/E of -3.5278 and an EV to EBITDA of -2.8670, highlighting a relative weakness in Vanda's financial standing.\n\nThe company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -5.64% compared to the index's 12.22%, and a staggering decline of -54.62% over the past three years versus the S&P's 70.41% gain. This stark contrast reinforces the view that Vanda Pharmaceuticals is overvalued in the current market environment...."
      }
    ],
    "total": 11,
    "sid": "1162364",
    "stock_news_url": "https://www.marketsmojo.com/news/vanda-pharmaceuticals-inc-1162364"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Vanda Pharmaceuticals Hits New 52-Week High at $5.62

2025-10-27 16:50:44

Vanda Pharmaceuticals, Inc. achieved a new 52-week high of USD 5.62 on October 24, 2025, despite a 1-year performance decline of 8.03%. The company, with a market capitalization of USD 269 million, is currently loss-making and does not offer dividends, reflecting its challenges in the pharmaceutical sector.

Vanda Pharmaceuticals Hits New 52-Week High of $5.59

2025-10-09 20:08:43

Vanda Pharmaceuticals, Inc. achieved a new 52-week high of USD 5.59 on October 8, 2025, despite a 1-year performance decline of 8.7%. The company, with a market capitalization of USD 269 million, remains loss-making and does not offer a dividend yield, reflecting its growth stage in the pharmaceuticals industry.

Vanda Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-06 15:28:41

Vanda Pharmaceuticals, Inc. has recently achieved a Golden Cross, indicating a potential shift in market sentiment. The stock has shown strong daily and weekly performance, outperforming the S&P 500. Despite past declines over three and five years, recent bullish indicators suggest renewed investor interest in the company.

Vanda Pharmaceuticals Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-09-24 14:19:54

Vanda Pharmaceuticals has recently encountered a Death Cross, indicating a potential shift in market sentiment. Technical indicators present a mixed outlook, with some showing bullish momentum while others suggest short-term challenges. Over the long term, the company has underperformed significantly compared to the S&P 500, raising investor concerns.

Is Vanda Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:48:20

As of 11 September 2025, the technical trend for Vanda Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing both bullish and bearish signals. The MACD is mildly bullish on both weekly and monthly time frames, while the daily moving averages also indicate a mildly bullish trend. However, the KST, Dow Theory, and OBV are all mildly bearish on the weekly and monthly time frames, suggesting underlying weakness. The Bollinger Bands show a sideways trend weekly but bearish monthly. In terms of performance, Vanda Pharmaceuticals has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.64% versus the S&P 500's 12.22%, and a one-year return of -8.69% compared to 17.14% for the index....

Is Vanda Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:23:19

As of 8 May 2024, the valuation grade for Vanda Pharmaceuticals, Inc. has moved from expensive to risky, indicating a significant downgrade in its perceived value. The company is currently considered overvalued based on its financial metrics, particularly with a Price to Book Value of 0.53, an EV to EBIT of 0.89, and an EV to EBITDA of 1.00. Compared to peers, Vanda's valuation ratios are less favorable, with Lexicon Pharmaceuticals, Inc. showing a P/E of -3.5278 and an EV to EBITDA of -2.8670, highlighting a relative weakness in Vanda's financial standing. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -5.64% compared to the index's 12.22%, and a staggering decline of -54.62% over the past three years versus the S&P's 70.41% gain. This stark contrast reinforces the view that Vanda Pharmaceuticals is overvalued in the current market environment....

View All News